Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 7/20 | 0.76 |
| ▸ | AGTR1 | P30556 | 6/20 | 0.76 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9032647 | 0.90 | AGTR1 (0.61) | AGTR2AGTR1ACHE | |
| SCHEMBL8392990 | 0.81 | AGTR1 (0.76) | AGTR2AGTR1 | |
| SCHEMBL7444657 | 0.81 | AGTR1 (0.55) | AGTR2AGTR1ACHE | |
| SCHEMBL440 | 0.80 | AGTR2 (0.61) | AGTR2AGTR1 | |
| SCHEMBL7305298 | 0.80 | AGTR1 (0.58) | AGTR2AGTR1 | |
| SCHEMBL7308185 | 0.80 | AGTR1 (0.54) | AGTR2AGTR1ACHE | |
| SCHEMBL9007507 | 0.80 | ACHE (0.53) | AGTR2AGTR1ACHE | |
| SCHEMBL8392609 | 0.80 | AGTR1 (0.59) | AGTR2AGTR1 | |
| SCHEMBL1256252 | 0.79 | AGTR2 (0.66) | AGTR2AGTR1 | |
| SCHEMBL7311709 | 0.79 | AGTR1 (0.54) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | G.D. SEARLE & CO. (US) | 2001-09-06 | — | — | US | disclosed |
| WO-1991018888-A1 | N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | NR3C2, AGTR1, PAH | AGTR2 8/4885AGTR1 2/4885ACHE 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.